RU2013120607A - METHOD FOR INDIRECT ASSESSMENT OF SENSITIVITY OF LUNG CANCER CELLS TO DOXORUBICIN ON THE BASIS OF EXPRESSION LEVELS OF MARKER GENES AND KIT FOR ITS IMPLEMENTATION - Google Patents
METHOD FOR INDIRECT ASSESSMENT OF SENSITIVITY OF LUNG CANCER CELLS TO DOXORUBICIN ON THE BASIS OF EXPRESSION LEVELS OF MARKER GENES AND KIT FOR ITS IMPLEMENTATION Download PDFInfo
- Publication number
- RU2013120607A RU2013120607A RU2013120607/10A RU2013120607A RU2013120607A RU 2013120607 A RU2013120607 A RU 2013120607A RU 2013120607/10 A RU2013120607/10 A RU 2013120607/10A RU 2013120607 A RU2013120607 A RU 2013120607A RU 2013120607 A RU2013120607 A RU 2013120607A
- Authority
- RU
- Russia
- Prior art keywords
- sensitivity
- lung cancer
- expression levels
- cancer cells
- marker genes
- Prior art date
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
1. Способ косвенной оценки чувствительности клеток рака легкого к доксорубицину на основании уровней экспрессии маркерных генов ABCC1, ERCC1, FTL, GSTP1, МТ2А, RRM1, TUBB3, которые определяют с помощью гибридизации флуоресцентно меченых препаратов нуклеиновых кислот, приготовленных из клеток, со специфическими олигонуклеотидными зондами, иммобилизованными на твердой подложке.2. Набор специфических олигонуклеотидных зондов, предназначенных для осуществления изобретения.1. A method for indirectly evaluating the sensitivity of lung cancer cells to doxorubicin based on the expression levels of marker genes ABCC1, ERCC1, FTL, GSTP1, MT2A, RRM1, TUBB3, which are determined by hybridization of fluorescently labeled nucleic acid preparations prepared from cells with specific oligonucleotide probes immobilized on a solid substrate. 2. A set of specific oligonucleotide probes for carrying out the invention.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013120607/10A RU2528247C2 (en) | 2013-05-07 | 2013-05-07 | Method of evaluation of sensitivity of lung cancer cells to doxorubicin based on expression levels of marker genes and set for its implementation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013120607/10A RU2528247C2 (en) | 2013-05-07 | 2013-05-07 | Method of evaluation of sensitivity of lung cancer cells to doxorubicin based on expression levels of marker genes and set for its implementation |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2013120607A true RU2013120607A (en) | 2013-09-27 |
RU2528247C2 RU2528247C2 (en) | 2014-09-10 |
Family
ID=49253802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013120607/10A RU2528247C2 (en) | 2013-05-07 | 2013-05-07 | Method of evaluation of sensitivity of lung cancer cells to doxorubicin based on expression levels of marker genes and set for its implementation |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2528247C2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108866185A (en) * | 2017-05-16 | 2018-11-23 | 肿瘤学风险公司 | Method for predicting the medicine response in cancer patient |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
FI3198035T3 (en) | 2014-09-26 | 2023-01-31 | Methods for predicting drug responsiveness | |
US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010059742A1 (en) * | 2008-11-18 | 2010-05-27 | Collabrx, Inc. | Individualized cancer treatment |
ES2763899T3 (en) * | 2009-07-08 | 2020-06-01 | Worldwide Innovative Network | Method for predicting drug efficacy in a patient |
WO2012024543A1 (en) * | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
RU2458131C1 (en) * | 2010-12-07 | 2012-08-10 | Федеральное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта | Test system for mutation detection in human fumarylacetoacetate hydrolase and alpha-1-antitrypsin genes |
-
2013
- 2013-05-07 RU RU2013120607/10A patent/RU2528247C2/en active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108866185A (en) * | 2017-05-16 | 2018-11-23 | 肿瘤学风险公司 | Method for predicting the medicine response in cancer patient |
Also Published As
Publication number | Publication date |
---|---|
RU2528247C2 (en) | 2014-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX367666B (en) | Compositions and methods for quantifying a nucleic acid sequence in a sample. | |
EA202090290A1 (en) | APPLICATION OF PROTEIN Cas, METHOD FOR DETECTING TARGET NUCLEIC ACID MOLECULE AND KIT | |
GB2526736A (en) | Methods, compositions, and kits for nucleic acid analysis | |
AU2017257624A1 (en) | Hybridization chain reaction methods for in situ molecular detection | |
EA201692157A1 (en) | SYNTHESIS OF TWO-CELLULAR NUCLEIC ACIDS | |
BR112017008082A2 (en) | compositions and methods for detecting an rna virus | |
AR102518A1 (en) | METHODS AND BIOMARKERS TO PREACH THE EFFECTIVENESS AND EVALUATION OF AN OX40 AGONIST TREATMENT | |
EA201492114A1 (en) | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION | |
WO2014182528A3 (en) | Multiplex labeling of molecules by sequential hybridization barcoding | |
MX2019007814A (en) | Gene expression profile algorithm and test for determining prognosis of prostate cancer. | |
EA201600085A1 (en) | KIT FOR DETECTION OF SOYO SYNT SYNT0H2 EVENT | |
WO2014144657A3 (en) | Compositions and methods for cancer prognosis | |
RU2013120607A (en) | METHOD FOR INDIRECT ASSESSMENT OF SENSITIVITY OF LUNG CANCER CELLS TO DOXORUBICIN ON THE BASIS OF EXPRESSION LEVELS OF MARKER GENES AND KIT FOR ITS IMPLEMENTATION | |
EA201492123A1 (en) | COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE SMN GENES FAMILY | |
BR112013010856A2 (en) | test for gardnerella vaginalis | |
EA201201036A1 (en) | TARGETED GENOMIC CHANGES | |
MX2017001405A (en) | Detection of target nucleic acids using hybridization. | |
TR201819546T4 (en) | Determination methods for specimen species origin. | |
BR112015023769A2 (en) | analytical instrument systems | |
UA115321C2 (en) | Methods and compositions for analyzing ahasl genes in wheat | |
EA201990730A1 (en) | RNA BIOMARKERS FOR HEREDITARY ANGIONEUROTIC Edema | |
WO2016059473A3 (en) | Sequence conversion and signal amplifier dna having locked nucleic acids and detection methods using same | |
BR112013004044A2 (en) | compositions and methods for quantifying a nucleic acid sequence in a sample. | |
MX369911B (en) | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer. | |
GB2542576A (en) | Method and kit of detecting the absence of micro-oranisms |